Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

West Clinic PC

Neither a doctor nor a teaching hospital

Research payments

$994,341

160 payments

Through program year 2025, West Clinic PC is reported as receiving $994,341 in research payments, across 160 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $61,918 10
2024 Research $41,503 7
2023 Research $115,897 7
2022 Research $186,273 37
2021 Research $55,785 9
2020 Research $202,636 54
2019 Research $330,330 36

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $399,591 59 payments
  2. Amgen Inc. $149,744 5 payments
  3. Pfizer Inc. $107,694 27 payments
  4. Daiichi Sankyo Inc. $102,102 32 payments
  5. Seattle Genetics, Inc. $92,558 5 payments
  6. Regeneron Pharmaceuticals, Inc. $72,623 13 payments
  7. Radius Health, Inc. $55,642 7 payments
  8. Medivation Inc. $7,482 6 payments
  9. Stemline Therapeutics Inc. $5,754 4 payments
  10. Celgene Corporation $1,007 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Ipatasertib in Combination With Paclitaxel in TNBC and HR Breast Cancer $160,559 11 payments
  2. A Phase III Trial of GDC 9545 in Combination With Palbo in HR Her2 Neg 1L MBC $104,766 13 payments
  3. A Randomized Doubleblind Phase 3 Study of Avelumab in Combination With Standard of Care Chemoradiotherapy Cisplatin Plus Definitive Radiation Therapy Versus Standard of Care Chemoradiotherapy in the Frontline Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck $83,440 25 payments
  4. An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy with Optional Maintenance Therapy in Subjects with HER2 Expressing Previously Untreated Locally Advanced or Metastatic Urothelial Cancer $79,058 3 payments
  5. A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels $72,623 13 payments
  6. P1/3 talimogene laherparepvec + MK-3475 Combo melanoma $69,425 2 payments
  7. A Randomized, Multicenter, Phase 2 Study Of Elacestrant (rad1901) Versus Investigators Choice Of Fulvestrant Or Aromatase Inhibitor Therapy For The Treatment Of Postmenopausal Women With Er+/her2- Breast Cancer $55,642 7 payments
  8. 1L Mtnbc Ipatasertib Tecentriq Paclitaxel $44,149 4 payments
  9. A Phase 1b trial of talimogene laherparepvec in combination with dabrafenib and trametinib in advanced melanoma with an activating BRAF mutation $39,474 1 payment
  10. Tumor Agnostic Precision Immuno Oncology and Somatic Targeting Rational for You Tapistry Phase II $36,445 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record